<?xml version="1.0" encoding="UTF-8"?>

<document id="DDI-DrugBank.d602"> 
   <sentence id="DDI-DrugBank.d602.s0" text="Caution is recommended when administering NEXAVAR with compounds that are metabolized/eliminated predominantly by the UGT1A1 pathway (e.g. irinotecan). " new_text="Caution@@is@@recommended@@when@@administering@@NEXAVAR@@with@@compounds@@that@@are@@metabolized/eliminated@@predominantly@@by@@the@@UGT1A1@@pathway@@(e.g@@.@@irinotecan@@)@@.@@"> 
      <entity id="DDI-DrugBank.d602.s0.e0" charOffset="42-48" type="brand" text="NEXAVAR" position="5"/>  
      <entity id="DDI-DrugBank.d602.s0.e1" charOffset="139-148" type="drug" text="irinotecan" position="18"/>  
      <pair id="DDI-DrugBank.d602.s0.p0" e1="DDI-DrugBank.d602.s0.e0" e2="DDI-DrugBank.d602.s0.e1" ddi="true" type="advise" flags="True" e1_name="NEXAVAR" e2_name="irinotecan" e1_pos="5" e2_pos="18" path="5@@4@@7@@10@@19@@18@@">NEXAVAR@@@@dobj@@administering@@prep_with@@compounds@@rcmod@@metabolized/eliminated@@agent@@)@@amod@@irinotecan</pair> 
   </sentence>  
   <sentence id="DDI-DrugBank.d602.s1" text="Concomitant treatment with NEXAVAR resulted in a 21% increase in the AUC of doxorubicin. " new_text="Concomitant@@treatment@@with@@NEXAVAR@@resulted@@in@@a@@21%@@increase@@in@@the@@AUC@@of@@doxorubicin@@.@@"> 
      <entity id="DDI-DrugBank.d602.s1.e0" charOffset="27-33" type="brand" text="NEXAVAR" position="3"/>  
      <entity id="DDI-DrugBank.d602.s1.e1" charOffset="76-86" type="drug" text="doxorubicin" position="13"/>  
      <pair id="DDI-DrugBank.d602.s1.p0" e1="DDI-DrugBank.d602.s1.e0" e2="DDI-DrugBank.d602.s1.e1" ddi="true" type="mechanism" flags="True" e1_name="NEXAVAR" e2_name="doxorubicin" e1_pos="3" e2_pos="13" path="3@@1@@4@@11@@13@@">NEXAVAR@@@@prep_with@@treatment@@nsubj@@resulted@@prep_in@@AUC@@prep_of@@doxorubicin</pair> 
   </sentence>  
   <sentence id="DDI-DrugBank.d602.s2" text="Caution is recommended when administering doxorubicin with NEXAVAR. " new_text="Caution@@is@@recommended@@when@@administering@@doxorubicin@@with@@NEXAVAR@@.@@"> 
      <entity id="DDI-DrugBank.d602.s2.e0" charOffset="42-52" type="drug" text="doxorubicin" position="5"/>  
      <entity id="DDI-DrugBank.d602.s2.e1" charOffset="59-65" type="brand" text="NEXAVAR" position="7"/>  
      <pair id="DDI-DrugBank.d602.s2.p0" e1="DDI-DrugBank.d602.s2.e0" e2="DDI-DrugBank.d602.s2.e1" ddi="true" type="advise" flags="True" e1_name="doxorubicin" e2_name="NEXAVAR" e1_pos="5" e2_pos="7" path="5@@4@@7@@">doxorubicin@@@@dobj@@administering@@prep_with@@NEXAVAR</pair> 
   </sentence>  
   <sentence id="DDI-DrugBank.d602.s3" text="Sorafenib inhibits CYP2B6 and CYP2C8 in vitro with Ki values of 6 and 1-2 ?M, respectively. " new_text="Sorafenib@@inhibits@@CYP2B6@@and@@CYP2C8@@in@@vitro@@with@@Ki@@values@@of@@6@@and@@1-2@@?M@@,@@respectively@@.@@"> 
      <entity id="DDI-DrugBank.d602.s3.e0" charOffset="0-8" type="drug" text="Sorafenib" position="0"/> 
   </sentence>  
   <sentence id="DDI-DrugBank.d602.s4" text="Systemic exposure to substrates of CYP2B6 and CYP2C8 is expected to increase when co-administered with NEXAVAR. " new_text="Systemic@@exposure@@to@@substrates@@of@@CYP2B6@@and@@CYP2C8@@is@@expected@@to@@increase@@when@@co-administered@@with@@NEXAVAR@@.@@"> 
      <entity id="DDI-DrugBank.d602.s4.e0" charOffset="103-109" type="brand" text="NEXAVAR" position="15"/> 
   </sentence>  
   <sentence id="DDI-DrugBank.d602.s5" text="Caution is recommended when administering substrates of CYP2B6 and CYP2C8 with NEXAVAR." new_text="Caution@@is@@recommended@@when@@administering@@substrates@@of@@CYP2B6@@and@@CYP2C8@@with@@NEXAVAR@@.@@"> 
      <entity id="DDI-DrugBank.d602.s5.e0" charOffset="79-85" type="brand" text="NEXAVAR" position="11"/> 
   </sentence> 
</document>
